Filter Results:
(3,822)
Show Results For
- All HBS Web
(3,822)
- People (6)
- News (663)
- Research (2,683)
- Events (46)
- Multimedia (43)
- Faculty Publications (1,502)
Show Results For
- All HBS Web
(3,822)
- People (6)
- News (663)
- Research (2,683)
- Events (46)
- Multimedia (43)
- Faculty Publications (1,502)
- Research Summary
The Role of the Internet in Enhancing Service and Reducing Cost
Is delivering service (both internal and external) facilitated by the Internet a zero sum game in which costs associated with delivering superior service must always be passed on to customers in the form of higher prices? Does the quantity and type of service... View Details
- January 2024
- Article
Population Interference in Panel Experiments
By: Kevin Wu Han, Guillaume Basse and Iavor Bojinov
The phenomenon of population interference, where a treatment assigned to one experimental unit affects another experimental unit’s outcome, has received considerable attention in standard randomized experiments. The complications produced by population interference in... View Details
Han, Kevin Wu, Guillaume Basse, and Iavor Bojinov. "Population Interference in Panel Experiments." Journal of Econometrics 238, no. 1 (January 2024).
- 2011
- Working Paper
Fiduciary Duties and Equity-Debtholder Conflicts
By: Bo Becker and Per Stromberg
We use an important legal event as a natural experiment to examine the effect of management fiduciary duties on equity-debt conflicts. A 1991 Delaware bankruptcy ruling changed the nature of corporate directors' fiduciary duties in firms incorporated in that state.... View Details
Keywords: Borrowing and Debt; Capital Structure; Equity; Insolvency and Bankruptcy; Governing Rules, Regulations, and Reforms; Laws and Statutes; Conflict and Resolution; Welfare or Wellbeing; Delaware
Becker, Bo, and Per Stromberg. "Fiduciary Duties and Equity-Debtholder Conflicts." Harvard Business School Working Paper, No. 10-070, February 2010. (Revised June 2011, November 2011.)
- August 2016 (Revised July 2017)
- Case
Diageo and Mey Icki: Turkish Delight or Turkish Hangover?
By: Dante Roscini and Gamze Yucaoglu
In September 2013, two years after its $2.1 billion acquisition of Mey Icki Sanayi ve Ticaret AS (Mey Icki), the principal spirits company in Turkey specializing in the local beverage, raki, Diageo, the world’s leading premium drinks company, was concerned about new... View Details
Keywords: Foreign Direct Investment; Emerging Markets; Government Legislation; Taxation; Valuation; Business and Government Relations; Government and Politics; Risk Management; Retail Industry; Food and Beverage Industry; Middle East; Turkey
Roscini, Dante, and Gamze Yucaoglu. "Diageo and Mey Icki: Turkish Delight or Turkish Hangover?" Harvard Business School Case 717-005, August 2016. (Revised July 2017.)
- 2022
- Working Paper
The Effect of Employee Lateness and Absenteeism on Store Performance
By: Caleb Kwon and Ananth Raman
We empirically analyze the effects of employee lateness and absenteeism on store performance by examining 25.5 million employee shift timecards covering more than 100,000 employees across more than 500 U.S. retail grocery store locations over a four year time period.... View Details
Kwon, Caleb, and Ananth Raman. "The Effect of Employee Lateness and Absenteeism on Store Performance." Working Paper, August 2022.
- July 2010 (Revised September 2011)
- Background Note
The Profession of the Law
By: Lena G. Goldberg and Chad Carr
This note reviews the professional responsibilities and obligations of lawyers In the United States, explains how those standards affect client relationships and, by summarizing rules for resolution of conflicts and withdrawal, sets the stage for a discussion of the... View Details
Keywords: Attorney and Client Relationships; Governing Rules, Regulations, and Reforms; Ethics; Standards; Legal Services Industry; United States
Goldberg, Lena G., and Chad Carr. "The Profession of the Law." Harvard Business School Background Note 311-028, July 2010. (Revised September 2011.)
- 17 Sep 2019
- News
Young People Are Going to Save Us All From Office Life
- 26 May 2020
- News
US And China Spare Over Coronavirus
- 03 Apr 2019
- News
Do Your Experiential Marketing Moves Produce Enough ROI?
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
Keywords: AI; Genetic Engineering; Medicine; Health Care and Treatment; Genetics; Innovation Strategy; Business and Stakeholder Relations; Medical Specialties; Innovation and Invention; Entrepreneurship; Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- 28 Nov 2012
- News
Executives’ Good Luck in Trading Own Stock
- 22 Jan 2012
- News
Achievement dilemmas
- 05 Jul 2006
- Working Paper Summaries
Do We Listen to Advice Just Because We Paid for It? The Impact of Cost of Advice on Its Use
- January 2008
- Article
Venture Capital Investment Cycles: The Impact of Public Markets
It is well documented that the venture capital industry is highly volatile and that much of this volatility is associated with shifting valuations and activity in public equity markets. This paper examines how changes in public market signals affected venture capital... View Details
Keywords: Market Cycles; Venture Capital; Investment; Experience and Expertise; Public Equity; Volatility; Financial Services Industry
Gompers, Paul, Anna Kovner, Josh Lerner, and David Scharfstein. "Venture Capital Investment Cycles: The Impact of Public Markets." Journal of Financial Economics 87, no. 1 (January 2008): 1–23. (Earlier versions distributed as National Bureau of Economic Research Working Paper No. 11385.)
The New CEO Activists
CEOs are increasingly taking a stand on divisive social issues that don't directly affect their companies' bottom lines—a dramatic departure from tradition. This Harvard Business Review... View Details
- 2010
- Chapter
Women and Leadership: Defining the Challenges
By: Robin J. Ely and Deborah L. Rhode
We use the experience of Carly Fiorina as an introduction to the continued challenges faced by women in top leadership roles. Although Fiorina, on becoming CEO of Hewlett Packard in 1999, asserted that "there is not a glass ceiling," her memoir eight years later... View Details
Ely, Robin J., and Deborah L. Rhode. "Women and Leadership: Defining the Challenges." Chap. 14 in Handbook of Leadership Theory and Practice, edited by Nitin Nohria and Rakesh Khurana. Harvard Business Press, 2010.
- Working Paper
Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing,... View Details
Keywords: Pharmaceuticals; Rebates; Health Care and Treatment; Markets; Price; Analysis; Pharmaceutical Industry
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S." NBER Working Paper Series, No. 26846, March 2020.